• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

From invasive to intuitive: The emerging role of non-invasive models in hepatic decompensation: Editorial on "Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)".

作者信息

Deshmukh Akhil, Maiwall Rakhi

机构信息

Department of Hepatology, Institute of Liver and Biliary Sciences, Delhi, India.

出版信息

Clin Mol Hepatol. 2025 Apr;31(2):577-580. doi: 10.3350/cmh.2024.0661. Epub 2024 Aug 19.

DOI:10.3350/cmh.2024.0661
PMID:39159945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12016586/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc4/12016586/938b6a2668a9/cmh-2024-0661f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc4/12016586/938b6a2668a9/cmh-2024-0661f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc4/12016586/938b6a2668a9/cmh-2024-0661f1.jpg

相似文献

1
From invasive to intuitive: The emerging role of non-invasive models in hepatic decompensation: Editorial on "Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)".从侵入性到直观性：非侵入性模型在肝失代偿中的新兴作用：关于“卡维地洛预防新的非侵入性模型（CHESS2306）分层的具有临床显著门静脉高压症的肝硬化患者肝失代偿”的社论
Clin Mol Hepatol. 2025 Apr;31(2):577-580. doi: 10.3350/cmh.2024.0661. Epub 2024 Aug 19.
2
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306).卡维地洛预防肝硬化肝失代偿：基于新的非侵入性模型（CHESS2306）分层的具有临床显著门静脉高压的患者
Clin Mol Hepatol. 2025 Jan;31(1):105-118. doi: 10.3350/cmh.2024.0198. Epub 2024 Jul 11.
3
Correspondence to editorial on "Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)".致关于“卡维地洛预防经新的非侵入性模型（CHESS2306）分层的具有临床显著门静脉高压的肝硬化患者肝失代偿”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e155-e157. doi: 10.3350/cmh.2024.0723. Epub 2024 Aug 30.
4
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.卡维地洛在竞争风险荟萃分析中降低了代偿性肝硬化患者失代偿和死亡的风险。
J Hepatol. 2022 Oct;77(4):1014-1025. doi: 10.1016/j.jhep.2022.05.021. Epub 2022 May 31.
5
Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China.卡维地洛预防肝硬度分层的临床显著门脉高压肝硬化失代偿的研究方案：中国一项随机、双盲、安慰剂对照、多中心试验。
BMJ Open. 2024 Jul 11;14(7):e081623. doi: 10.1136/bmjopen-2023-081623.
6
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.卡维地洛作为肝硬化和门静脉高压患者的新型非选择性β受体阻滞剂。
Liver Int. 2023 Jun;43(6):1183-1194. doi: 10.1111/liv.15559. Epub 2023 Apr 17.
7
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.β 受体阻滞剂预防有临床显著门静脉高压症的肝硬化失代偿（PREDESCI）：一项随机、双盲、安慰剂对照、多中心试验。
Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22.
8
Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.无创性检测方法对门静脉高压症的预测性能与肝静脉压力梯度相当。
J Hepatol. 2024 May;80(5):744-752. doi: 10.1016/j.jhep.2023.12.028. Epub 2024 Jan 11.
9
Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial.探索用于选择肝硬化患者非选择性β受体阻滞剂候选者的算法：PREDESCI试验的事后分析
J Hepatol. 2025 Mar;82(3):490-498. doi: 10.1016/j.jhep.2024.09.014. Epub 2024 Sep 19.
10
Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis.卡维地洛与普萘洛尔预防代偿期和失代偿期肝硬化患者病情恶化及降低死亡率的比较
J Hepatol. 2024 Dec 17. doi: 10.1016/j.jhep.2024.12.017.

引用本文的文献

1
Correspondence to editorial on "Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)".致关于“卡维地洛预防经新的非侵入性模型（CHESS2306）分层的具有临床显著门静脉高压的肝硬化患者肝失代偿”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e155-e157. doi: 10.3350/cmh.2024.0723. Epub 2024 Aug 30.

本文引用的文献

1
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306).卡维地洛预防肝硬化肝失代偿：基于新的非侵入性模型（CHESS2306）分层的具有临床显著门静脉高压的患者
Clin Mol Hepatol. 2025 Jan;31(1):105-118. doi: 10.3350/cmh.2024.0198. Epub 2024 Jul 11.
2
Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD.在非酒精性脂肪性肝病（NAFLD）中，肝脏硬度测量值的升高和降低与肝脏相关事件的风险独立相关。
J Hepatol. 2024 Oct;81(4):600-608. doi: 10.1016/j.jhep.2024.05.008. Epub 2024 May 16.
3
Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients.
比较连续和当前的肝脏硬度测量值以预测代偿期晚期慢性肝病患者的失代偿情况。
Hepatology. 2025 Feb 1;81(2):523-531. doi: 10.1097/HEP.0000000000000891. Epub 2024 Apr 17.
4
Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.肝硬度测量中的动力学变化可预测晚期慢性肝病的结局。
Gastroenterology. 2023 Oct;165(4):1041-1052. doi: 10.1053/j.gastro.2023.06.030. Epub 2023 Jul 11.
5
Validation of non-invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII.根据 Baveno VII，验证非侵入性诊断代偿性晚期慢性肝病患者的 CSPH。
Liver Int. 2023 Sep;43(9):1966-1974. doi: 10.1111/liv.15632. Epub 2023 Jun 8.
6
Spleen stiffness can predict liver decompensation and survival in patients with cirrhosis.脾脏硬度可预测肝硬化患者的肝脏失代偿及生存情况。
J Gastroenterol Hepatol. 2023 Feb;38(2):283-289. doi: 10.1111/jgh.16057. Epub 2022 Nov 18.
7
A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.一种联合 Baveno VII 和脾脏硬度算法，以改善代偿期慢性肝病患者临床显著门静脉高压的无创诊断。
Am J Gastroenterol. 2022 Nov 1;117(11):1825-1833. doi: 10.14309/ajg.0000000000001887. Epub 2022 Jul 21.
8
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识：门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
9
Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study.非侵入性工具与代偿性肝硬化临床显著门静脉高压和静脉曲张风险：“Anticipate”研究。
Hepatology. 2016 Dec;64(6):2173-2184. doi: 10.1002/hep.28824. Epub 2016 Oct 27.
10
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.肝静脉压力梯度可预测代偿期肝硬化患者的临床失代偿情况。
Gastroenterology. 2007 Aug;133(2):481-8. doi: 10.1053/j.gastro.2007.05.024. Epub 2007 May 21.